Victoza is Novo Nordisk's brand of liraglutide for type 2 diabetes. The second GLP-1 ever FDA-approved (after Byetta). Generic liraglutide approved 2024 provides lower-cost alternative.
At a glance
- Generic name: liraglutide
- Manufacturer: Novo Nordisk
- List price (cash, no coverage): ~$1,000/mo list
- Cash-pay program: Generic liraglutide available 2024+
FDA-approved indications
- Type 2 diabetes (2010)
- CV risk reduction in T2D + CVD (2017) — basis: LEADER
Standard dosing
- Start: 0.6 mg daily × 1 wk
- Then 1.2 mg, then 1.8 mg if needed